These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29661867)

  • 1. Triclosan Is an Aminoglycoside Adjuvant for Eradication of Pseudomonas aeruginosa Biofilms.
    Maiden MM; Hunt AMA; Zachos MP; Gibson JA; Hurwitz ME; Mulks MH; Waters CM
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29661867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential.
    Maiden MM; Zachos MP; Waters CM
    J Antimicrob Chemother; 2019 Apr; 74(4):894-906. PubMed ID: 30624737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
    Koeva M; Gutu AD; Hebert W; Wager JD; Yonker LM; O'Toole GA; Ausubel FM; Moskowitz SM; Joseph-McCarthy D
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.
    Yu Q; Griffin EF; Moreau-Marquis S; Schwartzman JD; Stanton BA; O'Toole GA
    J Antimicrob Chemother; 2012 Nov; 67(11):2673-81. PubMed ID: 22843834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mannitol enhances antibiotic sensitivity of persister bacteria in Pseudomonas aeruginosa biofilms.
    Barraud N; Buson A; Jarolimek W; Rice SA
    PLoS One; 2013; 8(12):e84220. PubMed ID: 24349568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of Tobramycin by Silver Nanoparticles against Pseudomonas aeruginosa Biofilms.
    Habash MB; Goodyear MC; Park AJ; Surette MD; Vis EC; Harris RJ; Khursigara CM
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model.
    Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of L-arginine on cystic fibrosis
    Eisha S; Morris AJ; Martin I; Yau YCW; Grasemann H; Waters V
    Antimicrob Agents Chemother; 2024 Aug; 68(8):e0033624. PubMed ID: 39023260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
    Breen SKJ; Harper M; López-Causapé C; Rogers KE; Tait JR; Smallman TR; Lang Y; Lee WL; Zhou J; Zhang Y; Bulitta JB; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
    Int J Antimicrob Agents; 2024 Jun; 63(6):107161. PubMed ID: 38561094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.
    Anderson GG; Kenney TF; Macleod DL; Henig NR; O'Toole GA
    Pathog Dis; 2013 Feb; 67(1):39-45. PubMed ID: 23620118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
    Bahamondez-Canas TF; Zhang H; Tewes F; Leal J; Smyth HDC
    Mol Pharm; 2018 Apr; 15(4):1643-1652. PubMed ID: 29514003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.
    Murphy RA; Coates M; Thrane S; Sabnis A; Harrison J; Schelenz S; Edwards AM; Vorup-Jensen T; Davies JC
    Microbiol Spectr; 2022 Aug; 10(4):e0081322. PubMed ID: 35727066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
    Field TR; White A; Elborn JS; Tunney MM
    Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures.
    Tré-Hardy M; Vanderbist F; Traore H; Devleeschouwer MJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):329-36. PubMed ID: 18280117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triclosan depletes the membrane potential in Pseudomonas aeruginosa biofilms inhibiting aminoglycoside induced adaptive resistance.
    Maiden MM; Waters CM
    PLoS Pathog; 2020 Oct; 16(10):e1008529. PubMed ID: 33125434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
    Treerat P; Widmer F; Middleton PG; Iredell J; George AM
    FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G; McKevitt M; Elborn JS; Tunney MM
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms.
    Haagensen J; Verotta D; Huang L; Engel J; Spormann AM; Yang K
    J Antimicrob Chemother; 2017 Dec; 72(12):3357-3365. PubMed ID: 28961810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.